Skip to main content
    A

    Akari Therapeutics PLC (AKTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.70
    -0.81 (-12.44%)

    Market Cap: $15.54M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Akari Therapeutics PLC (AKTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Akari Therapeutics (AKTX) has a market cap of $15.54M and an enterprise value of $9.80M. Its share count is up 20251.72% from a year earlier. It holds $5.74M more cash than debt, 36.96% of its market cap.

    Total Valuation

    Enterprise value is 36.96% below the market cap, as cash exceeds debt.

    Market Cap$15.54M
    Enterprise Value$9.80M
    Latest price (Nov 17, 2026)$5.70

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateAug 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 85.53% in the quarter ended Sep 30, 2026 and grew 2234.99% a year over 2 years.

    Shares Outstanding3.32M
    Shares Change (YoY)+20251.72%
    Shares Change (QoQ)+85.53%
    Share Count Growth (2Y CAGR)+2234.99%

    Price Statistics

    The stock is down 73.05% over 52 weeks and trades 34.63% below its 50-day average.

    Beta (1Y)2.33
    52-Week Change-73.05%
    1-Month Change-42.37%
    3-Month Change-27.85%
    6-Month Change+52.41%
    5-Year Change-99.38%
    10-Year Change-99.89%
    Total Return (1Y)-73.05%
    Total Return (3Y CAGR)-64.55%
    Total Return (5Y CAGR)-65.90%
    Return vs SPY (1Y)-84.70%
    Max Drawdown (1Y)-85.58%
    Max Drawdown (3Y)-98.22%
    Sharpe Ratio (1Y)-0.68
    Correlation with SPY (1Y)0.16
    50-Day Average$8.72
    200-Day Average$8.88
    52-Week Range$3.02 to $29.32
    RSI (14 Days)36.5
    Average Volume (20 Days)38.62K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.48x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio0.48x
    Quick Ratio0.48x
    Debt / Equity0.00x
    Interest Coverage-32.35x

    Returns and Efficiency

    Return on Assets (ROA)-84.64%
    ROIC (5Y Average)477.21%

    Scores

    AKTX has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Balance Sheet

    Cash and Equivalents$5.74M
    Total Debt$0
    Net Cash$5.74M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Dividends and Yields

    AKTX does not pay a dividend. Its free cash flow yield is -67.90%.

    FCF Yield-67.90%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-40 reverse split on Mar 31, 2026.

    Last Split DateMar 31, 2026
    Split TypeReverse split
    Split Ratio1:40

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About AKTX

    What is AKTX's market cap?

    Akari Therapeutics has a market cap of $15.54M. Its enterprise value, which adds debt and subtracts cash, is $9.80M.

    How many shares of AKTX are outstanding?

    Akari Therapeutics has 3.32M shares outstanding. The count is up 20251.72% from a year earlier.

    Does AKTX pay a dividend?

    No. Akari Therapeutics does not pay a dividend.

    How much debt does AKTX have?

    Akari Therapeutics has $0 of total debt and $5.74M of cash and equivalents, a net cash position of $5.74M.